Is the epigenome the "software" of the cell nucleus?

Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research.

Tune in today!

How do experienced troubleshooters solve a difficult problem? By asking the right questions first!

Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs.

Okay, let's start the podcast!

How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region.

In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval.

The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast.

Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of being a great communicator.

Okay, let's start the podcast!

How do mission, vision, and data analysis fit into today's biotech goals?

Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation.

Listen in to the latest episode of the Biorasi Few & Far Between podcast today!

How does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast!

Host Chris O'Brien welcomes Joshua Kresh, Emily Michiko Morris, and Mark Schultz from IPPI: The Intellectual Property Policy Institute. Tune in for a fascinating discussion on the dos and don'ts of IP protection.

Listen to the latest episode today!

How do you turn back the epigenetic clock for humans and their animal companions? 

Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Rejuvenate Bio, to the podcast. Tune in as we take a deep dive into parallel clinical trials designed to address chronic, age-related diseases in people and their pets. Plus, we'll zoom in on the right corporate structure for biotech products and the benefits of brainstorming.

Listen in to the latest episode of the Few & Far Between podcast today!

Now on the Few & Far Between podcast:

Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today's guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases.

Host Chris O'Brien welcomes Jonathan Rigby, Chairman and CEO at Sernova, to the podcast. Listen in as we spotlight Jonathan's 30-year industry journey, the development of implantable bio-hybrid organs, and how to plan for your first 30 days in a new biotech role.

Tune in today!

Today on the Biorasi Few & Far Between podcast:

What if you could read a story before its official release? Competitive intelligence gives you early access to information on emerging trends in clinical trials.

On today's episode, host Chris O'Brien welcomes Eileen Faucher. Eileen is the Principal and Founder of Brass Tacks Health, a company that provides insights that biotechs need to drive clinically-meaningful therapies.

Listen in to get the ROI on competitive intelligence, concise communications, and helping patients find relevant clinical trials.

Thanks for listening!

"You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio

Welcome back to Biorasi's Few & Far Between podcast. On today's episode, host Chris O'Brien welcomes John Celebi to the pocast.

Be sure to tune in for insights into assembling a core management team and how to build openness and inclusivity into biotech company culture.

Thank's for listening!